HEMATOLOGIC MALIGNANCIES

This study is for people aged 65 and older with blood cancers who are getting a stem cell transplant. Researchers want to find the safest lowest dose of a drug called cyclophosphamide, which is given after transplant to prevent the immune system from attacking the body. The goal …

This study provides ongoing treatment with tafasitamab for people with blood cancers who are already benefiting from the drug in an earlier study. It aims to keep the disease under control while monitoring for side effects. About 25 participants will join this extension study.

This study tests a new approach to prevent chronic graft-versus-host disease (GVHD), a common complication after stem cell transplants for blood cancers. About 40 adults will receive either the standard full-dose chemotherapy or a lower dose followed by the drug ruxolitinib. The …

This study is for people living with HIV who also have a blood cancer that can be treated with a bone marrow transplant. Researchers want to see if a new mix of three drugs can safely prevent graft-versus-host disease, a common complication after transplant. The study involves a …

This early-stage study tests a new drug called IM-1021 in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 117 adults will take part in this research.

This study tests an oral drug called MK-1026 (nemtabrutinib) in about 490 people with certain blood cancers, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenström's macroglobulinemia. The main goals are to check safety and see how well the drug shrinks or …

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers (like leukemia or lymphoma) or those who have had a stem cell transplant. Participants have a viral lung infection (PIV, hMPV, or RSV). The goal is to see if PUL-042 can prevent the infe…

This study tests a new approach for people with high-risk blood cancers like leukemia and lymphoma. It combines a half-matched bone marrow transplant with specially engineered immune cells (CAR T-cells) to attack the cancer. The goal is to see if giving both treatments together i…

This study tests a new drug called RJK-RT2831 for the first time in people with blood cancers. The main goal is to check its safety and find the best dose. About 71 adults aged 18 to 74 will take part. The drug is given as an injection.

This early-phase study tests a new drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The main goal is to check the drug's safety and find the right dose. Participants must have specific canc…

This study offers an extra infusion of stem cells from a half-matched family member to patients getting a cord blood transplant for serious blood cancers or immune disorders. The goal is to help the bone marrow recover faster while the cord blood cells take over permanently. It i…

This study tests a new combination of two drugs (ICP-248 and orelabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combo is safe and works well. About 226 adults aged 18 to 80 will take part. Because this is …

This study follows about 3,500 adults with solid tumors or blood cancers who are already taking or have taken pembrolizumab in earlier trials. Researchers will track long-term safety and how well the drug controls the disease over time. Participants may continue treatment or be m…

This study tests a new drug called SLS009 (formerly GFH009) in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also tests SLS009 combined with two other drugs (venetoclax and azacitidine) in certain patients. The goal is …

This study gives people with blood cancers, immune disorders, and other serious diseases access to unlicensed cord blood units for transplant. It includes both children and adults of any age. The main goal is to see how well the body recovers its white blood cells after the trans…

This study tests a lower dose of a drug called cyclophosphamide to prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers like leukemia. GVHD occurs when donor cells attack the patient's body. The goal is to see if the lower dose wor…

This study tests whether a cord blood transplant, given after a special conditioning therapy, can help control high-risk blood cancers in patients who relapsed after their first stem cell transplant. About 35 people aged up to 60 will take part. The main goal is to check safety a…

This study tests a personalized approach to stem cell transplants for adults with blood cancers like leukemia and lymphoma. The intensity of chemotherapy and radiation is adjusted based on each patient's risk level to try to improve survival and reduce side effects. About 60 part…

This study tests whether giving antibody replacements can prevent serious infections in people who have received CAR-T therapy for blood cancers. CAR-T therapy often lowers the body's natural antibodies, raising infection risk. The trial will compare antibody replacement to a pla…

This study tests whether a digital health app with remote monitoring can help 190 people receiving CAR-T therapy for blood cancers better manage their symptoms and reduce distress for their family caregivers. Participants use the app to report symptoms and receive support during …

This study is creating a large registry of lymphoma patients in Malawi to collect detailed information about the disease and its treatment. Researchers will enroll 800 people with suspected lymphoma, perform biopsies, and follow their health over time. The goal is to better under…

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like lymphoma, leukemia, or multiple myeloma. The tool helps patients clarify their personal values and shares that information with their doctors. The goal is to see if using PR…

This study watches how certain blood cancer drugs (BTK inhibitors or venetoclax) affect the heart's rhythm. About 135 adults with cancers like CLL or mantle cell lymphoma will have heart tests before and during treatment. The goal is to spot dangerous heart rhythms early and unde…

This study aims to understand how a protein called CD56 appears in different blood cancers, such as multiple myeloma and acute myeloid leukemia. Researchers will analyze blood or bone marrow samples from 38 newly diagnosed patients to see how common CD56 is and whether it relates…

This study is building a large registry of 15,000 people who received radiation therapy for cancer at Mayo Clinic. Researchers will collect medical information and biological samples to see how treatment affects side effects, quality of life, and survival. The goal is to learn fr…

This study looks at how the body processes the cancer drug pralatrexate in people with advanced solid tumors or blood cancers who also have mild, moderate, or severe liver problems. Researchers will measure drug levels in the blood and track side effects to find the safest dose. …